Long naps may increase the risk of chronic liver disease in people with diabetes
People with type 2 diabetes who nap longer than 30 minutes every day, regardless of their sleep patterns at night, increase their risk of developing metabolic dysfunction-associated steatotic liver disease…
Cohabitating people share about a quarter of their gut and oral microbiota
People who live together share more oral and gut microbes with each other than with other people in their communities, according to a study publishing June 15 in the Cell…
Study of 5.8 billion medicines dispensed in England exposes stark health inequalities
The team from the BHF Data Science Centre at Health Data Research UK and the University of Liverpool say this type of analysis can offer opportunities for smarter and safer…
Going up against the heat: Vertical greenery keeps cities cool
Ever stood in the middle of a city and just felt the heat radiating off its surfaces? Or entered a closed room and wondered how it could feel hotter than…
MIT researchers develop tiny ingestible sensor that can measure temperature from inside the body
In a hospital or at home, temperatures are usually taken using an oral or forehead thermometer, but these do not always accurately reflect the core body temperature. Measuring core temperature…
Women with HIV are more likely to die from trauma than the virus
Women with HIV most often die from preventable, trauma-related conditions like substance use and mental illness — not the virus itself. Yet, these leading causes are largely missing from official…
Stem Cell Transplantation More Cost-Effective than Gene Therapy for Sickle Cell Disease
Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared with gene therapy and standard of care treatment, according to new…
Pfizer’ s BRAFTOVI* Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer #ASCO26
Pfizer announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (ERBITUX®) and FOLFIRI…
#ASCO Urges congressional appropriators to support cancer research in FY27 budget
The Association for Clinical Oncology (ASCO) is asking congressional appropriators to allocate $51.3 billion to the National Institutes of Health (NIH) for Fiscal Year (FY) 2027. In written testimony submitted…
Experts call for women’s heart centres to tackle inequality in diagnosis & care
Women are more likely to face delays in diagnosis of cardiovascular disease and, as a result, they are more likely to die or develop more serious illness. To address this…